Using the new NSG-Pro recipient strain with ER+ PDX models, we uncovered evidence of actionable somatic BRCA1/2 pathway disruption in tamoxifen-resistant, isogenic PDX tumor sublines. Here, ESR1 is linked to neoplasm.